Archimedes Development Ltd clinical trials
Acquired by Kyowa Kirin Co., Ltd., Aug 5, 2014 · source ↗
The registry lists 5 studies whose lead sponsor is Archimedes Development Ltd. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Jan 15, 2014.
Before and after it joined Kyowa Kirin Co., Ltd.
- First submitted before Archimedes Development Ltd became part of Kyowa Kirin Co., Ltd.
- 5
- First submitted after Archimedes Development Ltd became part of Kyowa Kirin Co., Ltd.
- 0
- Unclear, or no submission date
- 0
By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.
Registry sponsor names on this page
- Archimedes Development Ltd5 studies
Something wrong with this grouping? Tell us on the Kyowa Kirin Co., Ltd. page.
Studies
Recruiting first, then most recently updated. Showing 5 of 5. All Kyowa Kirin Co., Ltd. studies →
- Patient Satisfaction and Quality of Life Impact - PecFent®Status unknownNCT01693328
Sponsor listed in the registry: Archimedes Development Ltd · First submitted before Archimedes Development Ltd became part of Kyowa Kirin Co., Ltd.
- Long Term Safety Study of Nasalfent (Fentanyl Citrate Nasal Spray) for Treatment of Breakthrough Cancer PainCompletedNCT00458510Phase 3
Sponsor listed in the registry: Archimedes Development Ltd · First submitted before Archimedes Development Ltd became part of Kyowa Kirin Co., Ltd.
- Patient Satisfaction and Quality of Life Impact - PecFent®Status unknownNCT01698645
Sponsor listed in the registry: Archimedes Development Ltd · First submitted before Archimedes Development Ltd became part of Kyowa Kirin Co., Ltd.
- Efficacy & Safety Study of Nasalfent (Fentanyl Citrate Nasal Spray) for Treatment of Breakthrough Cancer Pain in Patients Taking Regular OpioidsCompletedNCT00459277Phase 3
Sponsor listed in the registry: Archimedes Development Ltd · First submitted before Archimedes Development Ltd became part of Kyowa Kirin Co., Ltd.
- Efficacy and Safety Study of Nasalfent for Treatment of Breakthrough Cancer Pain in Patients Taking Regular OpioidsCompletedNCT00589823Phase 3
Sponsor listed in the registry: Archimedes Development Ltd · First submitted before Archimedes Development Ltd became part of Kyowa Kirin Co., Ltd.